ENGN
enGene Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENGN
Engene Holdings Inc.
A clinical-stage biotechnology company focused on non-viral gene therapies
4868 Rue Levy, Suite 220 Saint-Laurent, QC, Canada, H4R 2P1
--
EnGene Holdings Inc., was registered under the federal laws of Canada as 14963148 Canada Inc., on April 24, 2023, and changed its name to enGene Holdings Inc., on May 9, 2023. The company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The company is developing non-viral gene therapies based on its new and proprietary dual-derived chitosan, or "DDX" gene delivery platform, which allows local delivery of multiple gene cargoes directly to mucosal tissues and other organs.
Company Financials
EPS
ENGN has released its 2025 Q3 earnings. EPS was reported at -0.57, versus the expected -0.51, missing expectations. The chart below visualizes how ENGN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
